Rab28: A Protein Targeted for Cancer Therapies (G9364)

Target Name: RAB28

NCBI ID: G9364

RAB28

Rab28: A Protein Targeted for Cancer Therapies

Rab28 (also known as CORD18) is a protein that is expressed in many different tissues throughout the body. It is a member of the Rab family of GTPases, which are a type of protein that plays a critical role in cell signaling. Rab28 is well-known for its role in regulating cell proliferation and differentiation, and it is also a potential drug target.

The Rab family of GTPases are characterized by the presence of a GTPase domain, which is a structural region that is responsible for the binding of GTP (guanosine triphosphate). This domain is a key factor in the regulation of cell signaling pathways, as it allows the protein to recognize and respond to GTP-bound signaling molecules.

One of the key functions of Rab28 is its role in regulating cell proliferation. In many types of cancer, the loss of normal cell proliferation control is a hallmark feature. Rab28 is well-known for its ability to inhibit the activity of the oncogene p21, which is a key driver of cell proliferation. This inhibition allows cells to enter a state of checkpoint, where they are unable to continue dividing.

Another function of Rab28 is its role in regulating cell differentiation. During development, cells must be able to transition from one type of cell to another. This process is regulated by a complex interplay of signaling molecules, including the TGF-β pathway. Rab28 is well-known for its ability to regulate the activity of the TGF-β pathway, and it is a key regulator of the process of cell differentiation.

In addition to its roles in cell proliferation and differentiation, Rab28 is also well-known for its role in regulating cell survival. In many types of cancer, cells are able to evade the normal cell death signaling pathways, which are important for maintaining tissue homeostasis. Rab28 is well-known for its ability to regulate the activity of the apoptosis-associated protein (APO) gene, which is a key regulator of cell death.

The loss of normal cell proliferation and differentiation control is a hallmark feature of many types of cancer. Cancer cells are able to evade these normal controls through a variety of mechanisms, including the inhibition of signaling pathways that regulate cell growth and survival. Rab28 is well-known for its ability to inhibit the activity of the TGF-β pathway, which is a key regulator of cell growth and survival. This inhibition allows cancer cells to continue to divide and survive, which is a key feature of cancer growth.

In conclusion, Rab28 is a well-known protein that plays a critical role in the regulation of cell proliferation, differentiation, and survival. Its function as a potential drug target makes it an attractive target for the development of new cancer therapies. Further research is needed to fully understand the mechanisms of Rab28's function in cancer, and to develop effective therapies that take advantage of its potential as a drug target.

Protein Name: RAB28, Member RAS Oncogene Family

The "RAB28 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAB28 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets